Stumble, Recovery ... Fall?

 

This is an excerpt from Cabot China & Emerging Markets Report, which seeks to capitalize on the big boom in China and other emerging market countries. Editor Paul Goodwin, Cabot’s international investing guru, provides your passport to profits.



Sometimes during a foot-race, you’ll see a runner stumble, then seem to get his footing back. Then, after a few paces the runner loses it completely and falls in a heap.

While we don’t have a crystal ball, it’s possible that the situation in the Chinese stock market is following just such a pattern.

The Shanghai Composite Index is the Chinese equivalent of the Wilshire 5000 Index, a capitalization-based measure of all the stocks that trade on the exchange.

The Shanghai Composite topped out on June 12 at 5,166, capping a four-month run from 3,095. By July 3, the Shanghai Composite had retreated to 3687, a 29% decline. That’s the stumble we were talking about.

At that point, the Chinese government pulled out its entire arsenal of market supporting tools and pulled the trigger. Trading fees, margin requirements and borrowing rules were lowered, buying of stocks by government entities ramped up on a massive scale, the shorting of stocks was prohibited (and some short traders were arrested) and at least half the stocks on the Shanghai Exchange were withdrawn from trading.

The Shanghai Composite responded well to this program of support, popping to 4,124 on July 23. That’s the recovery.

But despite the program of support, the Composite was back below 3,600 (intraday) on July 29. And while the outcome of this clash of titans (The Government vs. Individual Investors) is still in doubt, it looks like the fall-in-a-heap phase may have kicked in.

We’ve already looked at the reasons for the souring of Chinese investors’ love for the market, but it’s safe to say that a major reason was the large number of inexperienced, uninformed investors who joined the rally late in its advance. By one estimate, there were 170,000 new stock trading accounts being opened every day in May and June on the Shanghai Exchange, which was more than 10 times the average for 2014. Euphoria was the order of the day.

And those enthusiastic late arrivers are the ones who really got murdered during the big correction. They won’t forget that disappearance of wealth anytime soon. If you think hell hath no fury like a woman scorned, you haven’t seen a naïve investor who came late to the party and lost his shirt.

The Cabot China & Emerging Markets Report’s portfolio has weathered this storm pretty well. We moved quickly to a heavier cash position by jettisoning our weakest performers and increased our exposure to non-Chinese stocks.

But China is still the Big Dog of the emerging markets, and we are watching closely to see which tendency comes out on top, the Recovery or the Collapse.

A researcher and writer for over 30 years, Paul Goodwin has been a member of the Cabot investment team and chief analyst of Cabot China & Emerging Markets Report since 2005.

Subscriber comments on Cabot China & Emerging Market Report


Paul Goodwin can be found on Google Plus.

Stock Picks

Ross Stores

McKesson (MCK) distributes ethical and proprietary drugs, surgical supplies and health and beauty products throughout North America to the healthcare industry. The company also provides technical consulting services to biotech and pharmaceutical manufacturers.

Carnival Cruise Lines

Having just returned from vacation, Tim Lutts is thinking of the millions of baby-boomers who are spending more and more money on leisure travel, particularly on cruises, an industry that is dominated by a few big players.

China Biologic Products

Paul Goodwin advises putting this stock on your watch list.

Cabot Wealth Advisory

Managing Your Stock Portfolio to the Market's Tune

By Michael Cintolo on July 30, 2015

In today’s Wealth Advisory, I’m doing something I’ve never done before—reprinting an entire piece I wrote in Cabot Growth Investor last Wednesday. It doesn’t involve any specific stock advice (that is and always will be for subscribers only), but it details the wild divergences in the market (which are now getting lots of press—even the Wall Street Journal had a big write-up on it Monday), what it means, and how I’m advising people to handle it—I think it’s very timely.Read More >

Do Your Stocks Have Borrowing Trouble?

By Nancy Zambell on July 28, 2015

Hostess is making news today as it is issuing $1.23 million in term loans—most of which will go toward paying $905 million in a special dividend to its private shareholders—which I may add, is also more than two times what the buyers paid for this tasty snack business, and triples the company’s debt. According to Bloomberg, these types of deals grew to nearly $16 billion in the second quarter, the highest level in the past 12 months. I’m not making a judgment for or against this action. I just want to make a point that this debt, or leverage recapitalization—spurred by low interest rates—is increasingly becoming a method in which private equity holders get their money back—without selling the business. But it does burden the company with additional debt, which isn’t going to fund company expansion or operations.Read More >

Sell Apple

By Timothy Lutts on July 27, 2015

Today, I’m writing on a MacBook Pro. This morning I did my morning crossword puzzle on my iPad. All day long, my iPhone is by my side. My home Wi-Fi comes from Apple AirPorts. And some nights, I stream entertainment through my Apple TV. In short, I love Apple products, and I expect to continue using them for many more years. But one of the most important market truisms is this: “The company is not the stock.”Read More >